Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,642.72
(
-1.09%
)
US TECH 100
23,944.80
(
-0.78%
)
Dow Jones
46,325.07
(
-1.42%
)
Brent Oil
105.02
(
4.34%
)
Bitcoin
71,097.42
(
-3.85%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ciotera post# 88617

Wednesday, 01/27/2010 2:28:43 AM

Wednesday, January 27, 2010 2:28:43 AM

Post# of 257253

…I do not agree that the "third agent paradigm" is here to stay indefinitely. Truvada may be the cleanest nuke but there are cleaner classes now, so I wouldn't be surprised to see nuke-sparing regimens come to dominate first line at some point because of improved tolerability.

According to GILD’s 4Q09 CC yesterday, Truvada is used by 81% of Isentress patients and 91% of Prezista patients in the first-line setting. If anything, the Truvada “paradigm” appears to be strengthening rather than weakening as new HIV agents are added to the armamentarium. Regards, Dew


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now